Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. Nishio S, et al. Among authors: usami t. Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15. Cancer Sci. 2022. PMID: 35792064 Free PMC article. Clinical Trial.
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082).
Furusawa A, Takekuma M, Mori K, Usami T, Kondo E, Nishio S, Nishino K, Miyamoto Y, Yoshimura R, Watanabe M, Mikami M, Enomoto T. Furusawa A, et al. Among authors: usami t. Int J Gynecol Cancer. 2021 Apr;31(4):623-626. doi: 10.1136/ijgc-2020-002344. Epub 2021 Mar 4. Int J Gynecol Cancer. 2021. PMID: 33664127 Clinical Trial.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, Olivera Hurtado de Mendoza M, Samouëlian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ; KEYNOTE-826 Investigators. Colombo N, et al. N Engl J Med. 2021 Nov 11;385(20):1856-1867. doi: 10.1056/NEJMoa2112435. Epub 2021 Sep 18. N Engl J Med. 2021. PMID: 34534429 Clinical Trial.
Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
Tanigawa T, Takeshima N, Ishikawa H, Nishio S, Usami T, Yamawaki T, Oishi T, Ihira K, Kato H, Goto M, Saito M, Taira Y, Yokoyama M, Shoji T, Kondo E, Mori A, Yokoi T, Iwasa-Inoue N, Hirashima Y, Nagasawa T, Takenaka M, Mikami M, Sugiyama T, Enomoto T. Tanigawa T, et al. Among authors: usami t. Gynecol Oncol. 2022 Jun;165(3):413-419. doi: 10.1016/j.ygyno.2022.04.011. Epub 2022 Apr 27. Gynecol Oncol. 2022. PMID: 35487773 Clinical Trial.
Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775.
Yonemori K, Yunokawa M, Ushijima K, Sakata J, Shikama A, Minobe S, Usami T, Enomoto T, Takehara K, Hasegawa K, Yamagami W, Yamamoto K, Han S, Dutta L, Orlowski R, Miura T, Makker V, Fujiwara K. Yonemori K, et al. Among authors: usami t. Cancer Sci. 2022 Oct;113(10):3489-3497. doi: 10.1111/cas.15436. Epub 2022 Jul 26. Cancer Sci. 2022. PMID: 35612971 Free PMC article. Clinical Trial.
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, Kim BG, Wang PH, Chang TC, Yamamoto K, Han S, McKenzie J, Orlowski RJ, Miura T, Makker V, Man Kim Y. Yonemori K, et al. Among authors: usami t. J Gynecol Oncol. 2024 Mar;35(2):e40. doi: 10.3802/jgo.2024.35.e40. Epub 2024 Jan 19. J Gynecol Oncol. 2024. PMID: 38302725 Free PMC article. Clinical Trial.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: usami t. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A, Christiaens M, Petru E, Usami T, Liu P, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Among authors: usami t. Lancet. 2024 Oct 5;404(10460):1321-1332. doi: 10.1016/S0140-6736(24)01808-7. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288779 Clinical Trial.
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.
Hasegawa K, Takahashi S, Ushijima K, Okadome M, Yonemori K, Yokota H, Vergote I, Monk BJ, Tewari KS, Fujiwara K, Li J, Jamil S, Paccaly A, Takehara K, Usami T, Aoki Y, Suzuki N, Kobayashi Y, Yoshida Y, Watari H, Seebach F, Lowy I, Mathias M, Fury MG, Oaknin A. Hasegawa K, et al. Among authors: usami t. Cancer Med. 2024 Sep;13(18):e70236. doi: 10.1002/cam4.70236. Cancer Med. 2024. PMID: 39325020 Free PMC article. Clinical Trial.
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.
Marth C, Moore RG, Bidziński M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. Marth C, et al. J Clin Oncol. 2024 Nov 26:JCO2401326. doi: 10.1200/JCO-24-01326. Online ahead of print. J Clin Oncol. 2024. PMID: 39591551
205 results